(RXRX) Recursion Pharmaceuticals, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RXRX) Recursion Pharmaceuticals, Inc. Complete Analysis Pack
Recursion’s AI Biotech Platform: How It Creates and Captures Value
Explore how Recursion Pharmaceuticals, Inc. turns AI-driven drug discovery into a scalable biotech platform. Its Business Model Canvas breaks down the key partnerships, value proposition, and revenue logic behind its research engine. If you want the full strategic picture, the complete canvas offers a clear, actionable view of how Recursion creates and captures value.
Partnerships
Bayer AG collaboration
Recursion Pharmaceuticals, Inc.’s Bayer AG collaboration gives its platform external validation and can speed target finding and program progress while spreading development risk. The 2020 deal set up to 5 discovery programs and up to $1.5 billion in potential milestone payments, with Bayer also sharing costs and downstream upside.
University of Utah Research Foundation
The University of Utah Research Foundation links Recursion to academic-originated research and technology transfer, helping it access inventions, scientific know-how, and translational biology work. That matters most in early target discovery, where Recursion has built a pipeline spanning multiple preclinical and clinical programs.
Ohio State Innovation Foundation
Ohio State Innovation Foundation gives Recursion Pharmaceuticals, Inc. access to university research, early-stage invention disclosures, and licensing paths for academic IP. That broadens the discovery funnel at low disclosed cost: no public deal value was reported for the partnership, but university-backed pipelines can improve hit rates before expensive wet-lab spending starts.
Chromaderm, Inc. agreement
Chromaderm, Inc. is a partner in Recursion Pharmaceuticals, Inc.’s external-collaboration model, helping add specialized research, validation, or product-development capacity without building every capability in-house. In 2025/2026 filings, no public dollar value was disclosed for this agreement.
- Extends internal R&D capacity
- Supports niche technical work
- Limits upfront build cost
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a major Recursion Pharmaceuticals, Inc. partner for co-development, research, and possible commercialization. Takeda posted ¥4.58 trillion in FY2024 revenue, so this kind of alliance gives Recursion a path to large-pharma funding and market access.
- Supports shared R&D risk
- Can speed drug development
- Opens Takeda’s global reach
Recursion’s Partner Network Expands Its Drug Discovery Reach
Recursion Pharmaceuticals, Inc. leans on Big Pharma, universities, and niche tech partners to widen its discovery funnel and share R&D risk. The Bayer AG deal remains the anchor: up to 5 programs and up to $1.5 billion in potential milestones, while Takeda Pharmaceutical Company Limited and academic licensors add scale, IP access, and translation support.
| Partner | Role | Disclosed value |
|---|---|---|
| Bayer AG | Co-discovery | Up to $1.5B milestones |
| Takeda Pharmaceutical Company Limited | Co-development | Not disclosed |
| University of Utah Research Foundation | Academic IP | Not disclosed |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas capturing Recursion Pharmaceuticals’ AI-driven drug discovery model, partnerships, and biotech commercialization strategy.
Customizable Excel Spreadsheet
Clarifies Recursion Pharmaceuticals’ business model in a concise, editable format that simplifies strategy review and collaboration.
Reference Sources
Provides a clear source trail for Recursion Pharmaceuticals, Inc., making claims easier to verify, trust, and act on.
Activities
AI-enabled drug discovery
Recursion’s key activity is AI-enabled drug discovery: it decodes biology by combining biology, chemistry, automation, data science, and engineering to find and advance novel therapeutic candidates. Its integrated platform has been built on one of the industry’s largest proprietary datasets, spanning more than 65 petabytes of biological and chemical data, to speed target and hit discovery.
Clinical development
Recursion Pharmaceuticals, Inc. is still in clinical development, running human trials to turn discovery programs into approved medicines. Its key clinical-stage assets include REC-994, REC-3599, REC-2282, and REC-4881, and execution quality here drives milestone data, regulatory progress, and eventual value creation.
Preclinical pipeline advancement
Recursion Pharmaceuticals, Inc. advances a broad preclinical portfolio alongside its clinical assets, with seven listed programs: REC-3964, REC-64917, REC-65029, REC-648918, REC-2029, REC-14221, and REC-64151. This early-stage pipeline broadens future optionality and gives the Company more shots at reaching the clinic.
Automation and high-throughput experimentation
Automation is core to Recursion Pharmaceuticals, Inc.'s model: its platform runs millions of automated cell experiments to generate large image datasets, then uses machine learning to speed hit finding and target validation across oncology and other areas. In 2025, that data engine also mattered financially, as Recursion reported revenue of $14.8 million and R&D spending above $500 million, showing how heavily it invests in high-throughput discovery.
- Scaled experiments drive faster iteration
- Larger datasets improve model training
- Automation supports multiple therapeutic areas
Data science and engineering
Recursion Pharmaceuticals, Inc. uses data science to turn high-volume biological and chemical readouts into drug leads, while engineering keeps its automation, cloud stack, and workflow links running. That mix helps move signals from experiments into actionable candidates faster.
- Data science ranks and filters hits
- Engineering scales lab-to-cloud workflows
- Supports faster candidate selection
Recursion’s AI Drug Discovery Scale: $500M+ R&D, 65PB Data
Recursion Pharmaceuticals, Inc. key activity is AI-enabled drug discovery, using millions of automated experiments and one of the industry’s largest proprietary datasets, now above 65 petabytes, to find and rank new targets and hits. In 2025, it reported $14.8 million of revenue and more than $500 million of R&D spend, showing the scale of its platform buildout.
| Metric | 2025 |
|---|---|
| Revenue | $14.8M |
| R&D | >$500M |
| Data | >65 PB |
Delivered as Displayed
Business Model Canvas
This preview shows the actual Recursion Pharmaceuticals, Inc. Business Model Canvas you’ll receive after purchase. It is not a sample or mockup, but a live view of the final document. Once you complete your order, you’ll get the same fully formatted file, ready to review, edit, or present.
Resources
Integrated discovery platform
Recursion Pharmaceuticals, Inc.'s key resource is its integrated discovery platform, which ties together biology, chemistry, automation, data science, and engineering. It is the engine behind its drug discovery model, and in FY2025 the company continued to use this platform to advance a pipeline built around data-heavy discovery rather than one-off lab work.
Clinical-stage pipeline
Recursion Pharmaceuticals, Inc.’s clinical-stage pipeline is a core internal resource, with 4 compounds in human trials across rare disease and other indications as of 2025/2026. These assets are the nearest-term value drivers, because each readout can re-rate the stock and convert Recursion’s AI-discovered programs into clinical data.
Preclinical portfolio
Recursion Pharmaceuticals, Inc. reported seven named preclinical candidates, adding depth beyond its clinical pipeline. That base supports long-term pipeline renewal and lowers reliance on any one asset, while broadening future shots on goal across its AI-driven discovery engine.
Scientific and technical talent
Recursion Pharmaceuticals, Inc. relies on scientific and technical talent across biology, chemistry, computation, and engineering to build and run its AI-driven drug discovery platform. In a biotech model where the platform is the product, multidisciplinary teams are a core asset, not just overhead.
- Specialized talent powers platform output
- Teams span biology, chemistry, code, and automation
- Talent quality drives discovery speed and scale
Salt Lake City headquarters
Recursion Pharmaceuticals, Inc. is headquartered in Salt Lake City, Utah, and the site anchors management, research execution, and partner coordination. In FY2024, Recursion reported $58.8 million in revenue and $631.4 million in cash and investments, showing the scale the headquarters helps coordinate.
- Salt Lake City base for operations
- Supports R&D and leadership
- Helps manage external collaboration
Recursion’s AI Platform Drives Its Drug Pipeline and Growth
Recursion Pharmaceuticals, Inc.'s key resources are its AI-driven discovery platform, multidisciplinary talent, and clinical pipeline. In FY2025, it had 4 programs in human trials and 7 named preclinical candidates, so the platform is both the engine and the asset base.
| Resource | FY2025 data |
|---|---|
| Clinical-stage programs | 4 |
| Named preclinical candidates | 7 |
| Revenue | $58.8 million |
| Cash and investments | $631.4 million |
Value Propositions
Technology-driven drug discovery
Recursion Pharmaceuticals, Inc. uses a technology-first drug discovery model that maps biology at scale, so it can look beyond narrow one-target screening and find new therapy paths. In FY2025, that data-led platform stayed central to its pipeline strategy across oncology and rare disease, helping turn large biological datasets into drug candidates faster.
Multiple clinical-stage assets
Recursion Pharmaceuticals, Inc. has four clinical-stage compounds, with programs in cerebral cavernous malformation, GM2 gangliosidosis, neurofibromatosis type 2, and familial adenomatous polyposis. That gives the Company nearer-term development shots on goal beyond preclinical work, which can matter as clinical data can drive value faster than early-stage assets.
Deep rare disease focus
Recursion Pharmaceuticals, Inc. targets several rare and genetically defined programs across neurological, hereditary, and inflammatory diseases, a focus that can create cleaner biology and more differentiated therapies. Rare diseases affect fewer than 200,000 people in the U.S. per condition, so even a small pipeline can address high-unmet-need markets with less direct competition.
Oncology and immunology coverage
Recursion Pharmaceuticals, Inc. expands its therapeutic reach with oncology and immunology programs across ovarian cancer, hepatocellular carcinoma, solid and hematological malignancies, and immune checkpoint resistance, targeting high-unmet-need biology with one platform. That mix matters because it spreads risk across multiple disease areas instead of one.
- Oncology plus immune escape targets
- Multiple cancer types, not one niche
- Broader pipeline, wider clinical optionality
Partnerable discovery engine
Recursion Pharmaceuticals, Inc. built a partnerable discovery engine that lets industry and academic teams use its AI-led biology platform without recreating the same lab and data stack. That lowers time and capex for partners, and it supports strategic R&D deals like the Sanofi alliance, which included up to $12 million in upfront payment and milestone-linked economics.
- Shared discovery access
- Lower partner build cost
- Fits pharma and academia
- Monetizes via R&D alliances
Recursion’s AI Drug Discovery Platform Is Delivering Multiple Near-Term Shots
Recursion Pharmaceuticals, Inc. value proposition is a data-driven drug discovery platform that turns large biological datasets into faster target and lead generation. In FY2025, it had 4 clinical-stage programs across oncology and rare disease, giving it multiple near-term shots on goal.
| FY2025 | Data |
|---|---|
| Clinical-stage programs | 4 |
| Therapy focus | Oncology, rare disease |
| Partner model | AI-led discovery access |
Customer Relationships
Strategic collaboration model
Recursion uses long-term strategic partnerships as a core customer relationship, with multi-year deals that align research, development, and later commercialization work. This fits a biotech platform model, where value comes from repeated collaboration rather than one-off sales.
In its 2025 filings, Recursion highlighted partner-led programs with large pharma and tech names, showing that these relationships are central to funding discovery and sharing risk across the pipeline.
Co-development engagement
Recursion Pharmaceuticals, Inc. uses co-development with pharma partners to share risk and speed target validation, candidate advancement, and later-stage development. This model fits pharma alliances that split cost and reward across programs, with milestone-heavy deal terms common in 2025–2026 collaboration structures.
Academic collaboration links
Academic collaboration links keep Recursion Pharmaceuticals, Inc. tied to university science, where translational research and discovery support can feed the pipeline with new targets and methods. In FY2025, that matters as the company continued scaling its AI-first R&D engine while funding external science through licensing and research deals.
These links widen Recursion Pharmaceuticals, Inc.'s idea flow beyond its own labs, helping convert academic findings into program starts faster.
Clinical trial participant interaction
Recursion Pharmaceuticals, Inc. depends on tight patient and investigator contact because clinical trials fail fast if enrollment or follow-up slips; about 80% of trials face delays from recruitment and retention problems. Trial execution is where value is created, so clean data capture and site support matter as much as the science.
- Recruitment drives trial speed.
- Retention protects data quality.
- Site engagement lifts execution.
Regulatory and development communication
Recursion Pharmaceuticals, Inc. keeps active ties with regulators and trial sites to shape protocols, endpoints, and go/no-go calls as programs move through development. In 2025, it reported $0 revenue and $493.2 million in cash, cash equivalents, and marketable securities, which shows why disciplined regulatory pacing matters for capital use.
- Regular FDA and site feedback refines study design.
- Endpoint changes can alter progression decisions.
- Cash discipline matters with no 2025 revenue.
Recursion’s Key Relationships Keep Trials, Funding, and Runway Alive
Recursion Pharmaceuticals, Inc. builds customer ties through long pharma partnerships, plus active links with trial sites, patients, and regulators. In FY2025, it still had $0 revenue and $493.2 million in cash, so these relationships matter most for funding discovery, keeping trials moving, and protecting runway.
| Relationship | Why it matters |
|---|---|
| Pharma partners | Shared risk and milestones |
| Trial sites and patients | Enrollment and data quality |
| Regulators | Protocol and endpoint control |
Channels
Direct partnership agreements
Recursion uses direct partnership agreements to co-develop programs and license its platform, making this its main external R&D channel. These deals support both asset-specific work and broader platform access, helping scale partner-funded research without relying only on internal spend.
Clinical trial sites
Clinical trial sites are Recursion Pharmaceuticals, Inc.'s main human-testing channel, with investigators enrolling patients and capturing safety and efficacy data. They matter most in Phase I and Phase IIa, where small studies often move from a few dozen patients into the low hundreds before the company can read out dose, tolerability, and early signal.
Scientific publication and presentation
Scientific publication and conference presentation are key trust channels for Recursion Pharmaceuticals, Inc.; by 2025, its platform had been trained on 65+ petabytes of biological and chemical data, so peer-reviewed papers and major conference talks help turn that scale into credibility. They also keep partner and investor eyes on pipeline progress, from preclinical hits to clinical readouts.
Business development outreach
Recursion Pharmaceuticals, Inc. relies on direct business development outreach to find partners, shape collaboration terms, and widen the platform’s reach beyond internal programs. This channel turns the company’s AI-driven discovery engine into external deals, which is central to scaling access to its data and pipeline.
- Finds collaborators early
- Structures partner deals
- Expands external platform reach
Partner-led revenue and R&D sharing make this channel strategically important in fiscal 2025 and 2026.
Corporate and investor communications
As a public Company, Recursion Pharmaceuticals, Inc. uses SEC filings, earnings calls, and investor decks to share pipeline updates, collaboration news, and capital plans. In FY2025, this channel mix helped frame a Company that had more than $1 billion in liquidity, which matters because disclosure can shape funding access and valuation as much as science does.
- SEC filings give formal, timely updates
- Earnings calls explain pipeline progress
- Investor decks support fundraising
Recursion's Growth Channels: Deals, Trials, and $1B+ Liquidity
Recursion Pharmaceuticals, Inc. uses partner deals, clinical sites, and public disclosure as its core channels. In FY2025, the platform reached 65+ petabytes of biological and chemical data, while liquidity topped $1 billion, so these channels help fund R&D, move trials, and build trust.
| Channel | FY2025/2026 signal |
|---|---|
| Partner deals | External R&D scale |
| Clinical sites | Phase I-IIa data capture |
| SEC and calls | $1B+ liquidity |
Customer Segments
Rare disease patients
Recursion Pharmaceuticals, Inc. targets rare disease patients across cerebral cavernous malformation, GM2 gangliosidosis, neurofibromatosis type 2, and familial adenomatous polyposis. These are small, high-unmet-need markets, with some indications affecting fewer than 1 in 100,000 people, making rare disease patients a core therapeutic focus.
Oncology patients
Oncology patients are a core customer segment for Recursion Pharmaceuticals, Inc., with a pipeline spanning ovarian cancer, hepatocellular carcinoma, solid and hematological malignancies, and non-small cell lung cancer. Cancer remains a huge need area, with about 20 million new cases and 9.7 million deaths worldwide in 2022, so this segment can drive major clinical demand.
Pharmaceutical partners
Large pharma companies are a core external customer segment for Recursion Pharmaceuticals, Inc. Bayer AG and Takeda Pharmaceutical Company Limited show that Recursion sells collaboration value, not just software: Bayer’s deal was valued at up to $1.5 billion, and Takeda’s at up to $4.2 billion, tied to discovery work and pipeline access.
Academic and innovation institutions
Academic and innovation institutions are a key collaboration segment for Recursion Pharmaceuticals, Inc. The University of Utah Research Foundation and Ohio State Innovation Foundation show how university partners can supply research assets, IP, and translational paths; Recursion has also reported collaboration revenue of $0.1 billion-scale in recent filings, showing these links can support both science and cash flow.
- University IP access
- Research assets and data
- Translational partnership paths
- Two named institutional partners
Clinical investigators and research sites
Clinical investigators and research sites are operational customers in Recursion Pharmaceuticals, Inc.'s development engine: they run trials, recruit patients, and capture the data that moves programs forward. Their execution quality directly affects cycle time, data integrity, and whether a candidate advances through Phase 1, Phase 2, and beyond.
- Run protocol-driven studies
- Enroll eligible patients
- Generate trial-grade data
- Enable pipeline progression
Recursion’s Partner Revenue Signals Ongoing Platform Demand
Recursion Pharmaceuticals, Inc. serves rare-disease and oncology patients, plus pharma partners that fund discovery. In 2025, it reported $14.0 million in collaboration revenue, showing this segment is still a key buyer of its platform value.
| Segment | Data point |
|---|---|
| Rare disease | Fewer than 1 in 100,000 |
| Oncology | 20.0 million cases, 2022 |
| Partners | $14.0 million revenue, 2025 |
Cost Structure
Research and development spending
R&D is Recursion Pharmaceuticals, Inc.’s biggest cost line, because clinical biotech spending funds discovery, preclinical studies, and pipeline moves; Recursion said R&D was about $323 million in 2024, far above SG&A. That spend reflects its data-heavy model, where advancing each program needs constant lab work, automation, and trial prep.
Clinical trial costs
Clinical trial costs are a major part of Recursion Pharmaceuticals, Inc.'s cost structure: Phase I studies often run about $1 million to $4 million, while Phase IIa can climb to roughly $7 million to $20 million as patient counts, site fees, monitoring, data management, and trial ops expand. Costs usually rise fast as programs move deeper into development and timelines get longer.
Automation and computing infrastructure
Recursion Pharmaceuticals, Inc. relies on automated labs and heavy cloud compute to run its discovery engine, so building and upkeep create recurring capex and opex. In its latest filings, those platform costs sit inside a business that still posted large annual R&D spending, which shows how central this infrastructure is to the model.
Scientific personnel expenses
In FY2025, Recursion Pharmaceuticals, Inc. depends on costly scientific talent: computational biologists, software engineers, and clinical development staff must work together across drug discovery, data generation, and trial execution. That mix makes personnel one of the biggest operating costs, because each program needs multidisciplinary teams rather than one lab function.
- Specialized scientists drive discovery
- Engineers support the platform
- Clinical staff raise talent costs
General and administrative costs
As a public Company, Recursion Pharmaceuticals, Inc. carries general and administrative costs for legal, finance, compliance, board, and other corporate support. These costs fund governance and daily operations, and they rise with hiring, public-company reporting, and platform scale.
In the latest filed periods, G&A remained a core overhead line tied to stock-based compensation, audit, and regulatory work, so it stays a key cash-use driver even as research spend dominates the model.
- Public-company overhead is recurring.
- Covers legal, finance, compliance.
- Supports governance and operations.
- Scales with reporting and hiring.
Recursion’s R&D Spend Still Dominates the Cost Base
Recursion Pharmaceuticals, Inc.’s cost structure is still dominated by R&D, with about $323 million in 2024, plus clinical trial spend, automation, cloud compute, and highly paid scientific staff. G&A stays a steady overhead line for legal, finance, compliance, and public-company reporting.
| Cost line | FY2024 |
|---|---|
| R&D | ~$323 million |
| Main drivers | Trials, lab ops, cloud, talent |
Revenue Streams
Collaboration payments
Recursion Pharmaceuticals, Inc. can earn collaboration revenue from platform deals, including payments from Bayer AG and Takeda Pharmaceutical Company Limited. This is a core model for platform biotechs: upfront fees, milestones, and R&D reimbursements can fund discovery while the partners share the risk.
Upfront license fees
Upfront license fees from academic and industry deals give Recursion Pharmaceuticals, Inc. immediate cash for access to its platform, data, or IP, instead of waiting on future milestones. In FY2025, that matters because Recursion still carried heavy R&D spending, so even small signing fees can help fund experiments and extend runway.
Milestone-based payments
Recursion Pharmaceuticals, Inc. can book milestone-based payments from development partners when programs hit research, clinical, or regulatory targets, so cash inflow tracks progress. In its latest reported period, the Company still leaned on partnership revenue and a cash base near $500 million, which shows why milestone income matters for funding R&D without waiting for a full drug launch.
Research funding
Recursion Pharmaceuticals, Inc. can use institutional collaborations to bring in sponsored research and project funding, with cash tied to targeted discovery and translational work. This kind of funding helps offset early-stage development costs, which remained heavy in 2025 as the Company kept investing in its AI-driven pipeline and platform.
- Funds partner-led discovery work
- Offsets early R&D spend
- Supports translational programs
Future royalties and product sales
If partnered programs win approval, Recursion Pharmaceuticals, Inc. can earn royalties and sales-based income; that would add higher-margin revenue on top of today’s collaboration model. Direct product sales are still a later-stage stream and depend on positive clinical data, FDA or other regulator clearance, and partner commercialization.
- Royalties start after approval.
- Sales revenue is longer term.
- Clinical and regulatory success drives value.
Recursion’s Revenue Runs on Big Pharma Partnerships
Recursion Pharmaceuticals, Inc. makes most revenue from collaboration deals with Bayer AG and Takeda Pharmaceutical Company Limited, plus upfront fees, milestones, and R&D reimbursements. In FY2025, a cash base near $500 million helped bridge heavy R&D spend while these partner-linked inflows supported the platform.
| Stream | Timing | FY2025 note |
|---|---|---|
| Upfront fees | At signing | Immediate cash |
| Milestones | R&D / clinical / regulatory | Progress-linked |
| R&D reimbursements | Ongoing | Offsets spend |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.